A Functional Polymorphism of the μ-Opioid Receptor Gene is Associated with Naltrexone Response in Alcohol-Dependent Patients
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
This study examined the association between two specific polymorphisms of the gene encoding the mu-opioid receptor and treatment outcomes in alcohol-dependent patients who were prescribed naltrexone or placebo. A total of 82 patients (71 of European descent) who were randomized to naltrexone and 59 who were randomized to placebo (all of European descent) in one of three randomized, placebo-controlled clinical trials of naltrexone were genotyped at the A(+118)G (Asn40Asp) and C(+17)T (Ala6Val) SNPs in the gene encoding the mu-opioid receptor (OPRM1). The association between genotype and drinking outcomes was measured over 12 weeks of treatment. In subjects of European descent, individuals with one or two copies of the Asp40 allele treated with naltrexone had significantly lower rates of relapse (p=0.044) and a longer time to return to heavy drinking (p=0.040) than those homozygous for the Asn40 allele. There were no differences in overall abstinence rates (p=0.611), nor were there differences in relapse rates or abstinence rates between the two genotype groups among those assigned to placebo. These preliminary results are consistent with prior literature demonstrating that the opioid system is involved in the reinforcing properties of alcohol and that allelic variation at OPRM1 is associated with differential response to a mu-receptor antagonist. If replicated, these results would help to identify alcohol-dependent individuals who may be most likely to respond to treatment wit…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“An initial retrospective analysis of NTX trials found that OPRM1 influenced treatment response, such that individuals with the Asp40 variant (G allele) receiving NTX had a longer time until the first heavy drinking day and were half as likely to relapse compared to those homozygous for the Asn40 variant (A allele) [92].”
From Relapse prevention for addictive behaviors (2011) · cites this paper as [92]
In the citing paper
“Interestingly, both human A118G subjects and Rhesus C77G subjects are more likely to respond positively to opioid antagonist therapy for alcoholism, which suggests that the differences in receptor properties may be a direct physiological mechanism for the increased risk for alcoholism (Oslin et al 2003).”
From The behavioral, anatomical and pharmacological parallels between social attachment, love and addiction (2012) · cites this paper as Oslin et al 2003
Citations
Cites
(1996) · Cited by 6,884
The fifth edition of the addiction severity index
McLellan, A. T., Kushner, H., Metzger, D., Peters, R., Smith, I., Grissom, G., Pettinati, H., & Argeriou, M. (1992) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(92)90062-s · Cited by 4,222 · cited 1×
“The Addiction Severity Index (ASI) was used to measure the severity of alcoholrelated problems during the pretreatment period (McLellan et al, 1980, 1992).”
MethodSelf-citationSobell, L. C., & Sobell, M. B. (1992) · Measuring Alcohol Consumption · doi:10.1007/978-1-4612-0357-5_3 · Cited by 4,110 · cited 1×
“The Time Line Follow-Back (TLFB) method measured alcohol consumption (Sobell et al, 1988; Sobell and Sobell, 1992) during the pretreatment and treatment periods.”
MethodMcLELLAN, A. T., LUBORSKY, L., WOODY, G. E., & O??BRIEN, C. P. (1980) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198001000-00006 · Cited by 3,188
Naltrexone in the Treatment of Alcohol Dependence
Volpicelli, J. R. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110040006 · Cited by 1,828
Self-citationNew Data from the Addiction Severity Index Reliability and Validity in Three Centers
McLELLAN, A. T., LUBORSKY, L., CACCIOLA, J., GRIFFITH, J., EVANS, F., BARR, H. L., & OʼBRIEN, C. P. (1985) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198507000-00005 · Cited by 1,503 · cited 1×
“…lifetime and recent (past 30 days) severity of problems in seven areas of biopsychosocial functioning (represented by component scores): medical status, employment and self-support, alcohol use, drug use, legal status, family and social relations, and psychiatric symptoms (McLellan et al, 1985).”
BackgroundSelf-citationNaltrexone and Coping Skills Therapy for Alcohol Dependence: A Controlled Study
O'Malley, S. S. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110045007 · Cited by 1,487 · cited 4×
“Although this definition of heavy drinking has been used in a number of pharmacotherapy trials (O’Malley et al, 1992; Volpicelli et al, 1992; Anton, 1996; Kranzler and VanKirk, 2001), both higher and lower levels of consumption could be considered significant.”
BackgroundMethodInfluentialBond, C., LaForge, K. S., Tian, M., Melia, D., Zhang, S., Borg, L., Gong, J., Schluger, J., Strong, J. A., Leal, S. M., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.16.9608 · Cited by 1,074 · cited 3×
“…association between OPRM1 sequence variation and the presence of alcohol and/or drug dependence (Bergen et al, 1997; Berrettini et al, 1997; Bond et al, 1998; Kranzler et al, 1998; Sander et al, 1998; Gelernter et al, 1999; Town et al, 1999; Hoehe et al, 2000; Franke et al, 2001;…”
BackgroundInfluentialSOBELL, L. C., SOBELL, M. B., LEO, G. I., & CANCILLA, A. (1988) · British Journal of Addiction · doi:10.1111/j.1360-0443.1988.tb00485.x · Cited by 776 · cited 1×
“The Time Line Follow-Back (TLFB) method measured alcohol consumption (Sobell et al, 1988; Sobell and Sobell, 1992) during the pretreatment and treatment periods.”
MethodNaltrexone in the Treatment of Alcohol Dependence
Krystal, J. H., Cramer, J. A., Krol, W. F., Kirk, G. F., & Rosenheck, R. A. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011127 · Cited by 618 · cited 1×
“…advantage of naltrexone over placebo (O’Malley et al, 1992; Volpicelli et al, 1992; Oslin et al, 1997; Chick et al, 2000; Anton et al, 2001; Monti et al, 2001; Morris et al, 2001), other studies have failed to show a significant drugplacebo difference (Kranzler et al, 2000; Krystal et al, 2001).”
BackgroundEfficacy of Naltrexone and Acamprosate for Alcoholism Treatment: A Meta‐Analysis
Kranzler, H. R., & Van Kirk, J. (2001) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2001.tb02356.x · Cited by 390 · cited 3×
“Although this definition of heavy drinking has been used in a number of pharmacotherapy trials (O’Malley et al, 1992; Volpicelli et al, 1992; Anton, 1996; Kranzler and VanKirk, 2001), both higher and lower levels of consumption could be considered significant.”
BackgroundMethodSelf-citationChick, J. (2000) · Alcohol and Alcoholism · doi:10.1093/alcalc/35.6.587 · Cited by 310 · cited 2×
“…of samples studied have shown a significant advantage of naltrexone over placebo (O’Malley et al, 1992; Volpicelli et al, 1992; Oslin et al, 1997; Chick et al, 2000; Anton et al, 2001; Monti et al, 2001; Morris et al, 2001), other studies have failed to show a significant drugplacebo difference…”
BackgroundEffect of naltrexone on alcohol “high” in alcoholics
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.4.613 · Cited by 308 · cited 1×
“Naltrexone has also been reported to block the euphoria produced by alcohol (Volpicelli et al, 1995; King et al, 1997).”
BackgroundSelf-citationHoehe, M. R. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.19.2895 · Cited by 290 · cited 1×
“…and/or drug dependence (Bergen et al, 1997; Berrettini et al, 1997; Bond et al, 1998; Kranzler et al, 1998; Sander et al, 1998; Gelernter et al, 1999; Town et al, 1999; Hoehe et al, 2000; Franke et al, 2001; Rommelspacher et al, 2001; Szeto et al, 2001; Schinka et al, 2002; Crowley et al, 2003).”
Lahiri, D. K., & Schnabel, B. (1993) · Biochemical Genetics · doi:10.1007/bf00553174 · Cited by 288 · cited 1×
“Genomic DNA was extracted from blood samples by standard methods (eg Lahiri and Schnabel, 1993).”
Methodμ opioid receptor gene variants: lack of association with alcohol dependence
Bergen, A. W., Kokoszka, J., Peterson, R., Long, J. C., Virkkunen, M., Linnoila, M., & Goldman, D. (1997) · Molecular Psychiatry · doi:10.1038/sj.mp.4000331 · Cited by 271 · cited 2×
“…studies have failed to demonstrate a consistent association between OPRM1 sequence variation and the presence of alcohol and/or drug dependence (Bergen et al, 1997; Berrettini et al, 1997; Bond et al, 1998; Kranzler et al, 1998; Sander et al, 1998; Gelernter et al, 1999; Town et al, 1999;…”
BackgroundInfluentialWand, G. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00294-9 · Cited by 246 · cited 2×
“Moreover, Wand et al (1998, 2002) found that both family history and the Asp40 variant explained some variance in the release of corticotrophin-releasing factor (CRF) after stimulation with naloxone.”
BackgroundGelernter, J., Kranzler, H., & Cubells, J. (1999) · Molecular Psychiatry · doi:10.1038/sj.mp.4000556 · Cited by 241 · cited 4×
“As the frequency distribution in the general population of the C+17T and A+118G SNPs differs significantly by ethnic origin (Gelernter et al, 1999), with few African Americans (AAs) having the A+118G SNP and few European Americans (EAs) having the C+17T SNP, analyses were limited to the allele of…”
BackgroundMethodInfluentialSelf-citationMonti, P. M., Rohsenow, D. J., Swift, R. M., Gulliver, S. B., Colby, S. M., Mueller, T. I., Brown, R. A., Gordon, A., Abrams, D. B., Niaura, R. S., et al. (2001) · Alcoholism: Clinical and Experimental Research · doi:10.1097/00000374-200111000-00011 · Cited by 233 · cited 2×
“…advantage of naltrexone over placebo (O’Malley et al, 1992; Volpicelli et al, 1992; Oslin et al, 1997; Chick et al, 2000; Anton et al, 2001; Monti et al, 2001; Morris et al, 2001), other studies have failed to show a significant drugplacebo difference (Kranzler et al, 2000; Krystal et al,…”
BackgroundStreeton, C. (2001) · Alcohol and Alcoholism · doi:10.1093/alcalc/36.6.544 · Cited by 228 · cited 1×
“Although the efficacy of naltrexone has been established in a number of randomized clinical trials, no trial has demonstrated efficacy for all subjects and, overall, the published clinical trials demonstrate only modest response effect sizes (Kranzler and VanKirk, 2001; Streeton and Whelan, 2001).”
BackgroundEnhanced Sensitivity of Pituitary βEndorphin to Ethanol in Subjects at High Risk of Alcoholism
Gianoulakis, C. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830030072011 · Cited by 227 · cited 2×
“Clearly, naltrexone does not help all alcohol-dependent adults and not all persons who drink alcohol show evidence of a ‘high’ (King et al, 1997) or an increase in endogenous opioids (Gianoulakis et al, 1996) induced by alcohol consumption.”
BackgroundKing, A. C., Volpicelli, J. R., Frazer, A., & O'Brien, C. P. (1997) · Psychopharmacology · doi:10.1007/s002130050156 · Cited by 227 · cited 3×
“Subjectively, some fraction of the rewarding effects of alcohol ingestion in high-risk subjects can be blocked by naltrexone (King et al, 1997).”
BackgroundSelf-citationNaltrexone vs. Nefazodone for Treatment of Alcohol Dependence A Placebo-Controlled Trial
Kranzler, H. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00135-9 · Cited by 209 · cited 4×
“The third study (study III), which involved 1 week of single-blind placebo treatment followed by 11 weeks of double-blind treatment, was conducted at the University of Connecticut Health Center between October 1993 and November 1996 (Kranzler et al, 2000).”
BackgroundMethodInfluentialSelf-citationPredicting Treatment Response to Naltrexone: The Influence of Craving and Family History
Monterosso, J. R., Flannery, B. A., Pettinati, H. M., Oslin, D. W., Rukstalis, M., O'Brien, C. P., & Volpicelli, J. R. (2001) · The American Journal on Addictions · doi:10.1080/105504901750532148 · Cited by 206 · cited 9×
“The specific procedures for the studies have been detailed in prior publications (Kranzler et al, 2000; Monterosso et al, 2001) and are briefly outlined here.”
BackgroundMethodInfluentialSelf-citationNaltrexone for alcohol dependence: a randomized controlled trial
Morris, P. L. P., Hopwood, M., Whelan, G., Gardiner, J., & Drummond, E. (2001) · Addiction · doi:10.1046/j.1360-0443.2001.961115654.x · Cited by 200 · cited 2×
“…advantage of naltrexone over placebo (O’Malley et al, 1992; Volpicelli et al, 1992; Oslin et al, 1997; Chick et al, 2000; Anton et al, 2001; Monti et al, 2001; Morris et al, 2001), other studies have failed to show a significant drugplacebo difference (Kranzler et al, 2000; Krystal et al, 2001).”
BackgroundNaltrexone blocks the post-shock increase of ethanol consumption
Volpicelli, J. R., Davis, M. A., & Olgin, J. E. (1986) · Life Sciences · doi:10.1016/0024-3205(86)90601-6 · Cited by 191 · cited 1×
“Prior animal and human studies have demonstrated that the opioid system is involved in the reinforcing effects of alcohol (Volpicelli et al, 1986, 1990; Kreek, 1996).”
BackgroundSelf-citationIMPLICATIONS OF ENDOGENOUS OPIOIDS AND DOPAMINE IN ALCOHOLISM: HUMAN AND BASIC SCIENCE STUDIES
GIANOULAKIS, C. (1996) · Alcohol and Alcoholism · doi:10.1093/oxfordjournals.alcalc.a008216 · Cited by 165 · cited 3×
“Alcohol has been found to increase endogenous opioids, especially in people with a family history of alcoholism (Gianoulakis, 1996).”
BackgroundJaffe, A. J., Rounsaville, B., Chang, G., & Schottenfeld, R. S. (1996) · Journal of Consulting and Clinical Psychology · doi:10.1037//0022-006x.64.5.1044 · Cited by 149
Association between mu opioid receptor gene polymorphisms and Chinese heroin addicts
Szeto, C. Y. K., Tang, N. L. S., Lee, D. T. S., & Stadlin, A. (2001) · Neuroreport · doi:10.1097/00001756-200105080-00011 · Cited by 144 · cited 1×
“…and/or drug dependence (Bergen et al, 1997; Berrettini et al, 1997; Bond et al, 1998; Kranzler et al, 1998; Sander et al, 1998; Gelernter et al, 1999; Town et al, 1999; Hoehe et al, 2000; Franke et al, 2001; Rommelspacher et al, 2001; Szeto et al, 2001; Schinka et al, 2002; Crowley et al, 2003).”
Hernandez‐Avila, C. A., Wand, G., Luo, X., Gelernter, J., & Kranzler, H. R. (2003) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.10054 · Cited by 144 · cited 1×
“Both Wand et al (2002) and Hernandez-Avila et al (2003) found that individuals with one or two copies of the Asp40 allele had altered HPA-axis activation induced by the opioid receptor antagonist naloxone, while Smolka et al (1999) showed that individuals with the Asp40 variant display greater…”
BackgroundSelf-citationNaltrexone as an Adjunctive Treatment for Older Patients With Alcohol Dependence
Oslin, D., Liberto, J. G., O'Brien, J., Krois, S., & Norbeck, J. (1997) · The American Journal of Geriatric Psychiatry · doi:10.1097/00019442-199700540-00007 · Cited by 143 · cited 3×
“…trials that have included a substantial proportion of AAs have not shown an effect of ethnicity on treatment response (Volpicelli et al, 1992; Oslin et al, 1997; Monterosso et al, 2001), there may be additional genetic predictors associated with naltrexone treatment response in this…”
BackgroundSelf-citationA genetic association study of the mu opioid receptor and severe opioid dependence
Crowley, J. J., Oslin, D. W., Patkar, A. A., Gottheil, E., DeMaria, P. A., O??Brien, C. P., Berrettini, W. H., & Grice, D. E. (2003) · Psychiatric Genetics · doi:10.1097/00041444-200309000-00006 · Cited by 135 · cited 2×
“…and/or drug dependence (Bergen et al, 1997; Berrettini et al, 1997; Bond et al, 1998; Kranzler et al, 1998; Sander et al, 1998; Gelernter et al, 1999; Town et al, 1999; Hoehe et al, 2000; Franke et al, 2001; Rommelspacher et al, 2001; Szeto et al, 2001; Schinka et al, 2002; Crowley et al, 2003).”
BackgroundInfluentialSelf-citationOpiates, opioids and addiction.
Kreek, M. J. (1996) · PubMed · Cited by 126
Family History of Alcoholism and Hypothalamic Opioidergic Activity
Wand, G. S., Mangold, D., El Deiry, S., McCaul, M. E., & Hoover, D. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.12.1114 · Cited by 119 · cited 1×
“Moreover, Wand et al (1998, 2002) found that both family history and the Asp40 variant explained some variance in the release of corticotrophin-releasing factor (CRF) after stimulation with naloxone.”
BackgroundFranke, P. E., Wang, T., Nöthen, M. M., Knapp, M., Neidt, H., Albrecht, S., Jahnes, E., Propping, P., & Maier, W. (2001) · PubMed · Cited by 119
Uncontrollable Events and Alcohol Drinking
VOLPICELLI, J. R. (1987) · British Journal of Addiction · doi:10.1111/j.1360-0443.1987.tb01494.x · Cited by 115 · cited 1×
“The use of naltrexone is based on an endorphin compensation model, suggesting that some alcohol-dependent individuals sustain a relative deficiency in endogenous opioids after experiencing a stressful event (Volpicelli, 1987; Volpicelli et al, 1990; Kreek, 1996).”
BackgroundSelf-citationJaffé, A., Rounsaville, B. J., Chang, G., et al. (1996) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.64.5.1044 · Cited by 108 · cited 1×
“Indeed, some clinical trials have shown family history to be a predictor of treatment response (Jaffe et al, 1996; Monterosso et al, 2001).”
BackgroundAssociation of a functional mu-opioid receptor allele (+118A) with alcohol dependency.
Town, T., Abdullah, L. I., Crawford, F., Schinka, J. A., Ordorica, P. I., Francis, E. M., Hughes, P. H., Duara, R., & MULLAN, M. J. (1999) · PubMed · Cited by 106
Assessment of Medication Compliance in Alcoholics through UV Light Detection of a Riboflavin Tracer
Del Boca, F. K., Kranzler, H. R., Brown, J., & Korner, P. F. (1996) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.1996.tb01142.x · Cited by 100 · cited 1×
“Adherence to the study medication regimen was monitored by self-report of medication use and by pill counts confirmed by weekly qualitative measurement of riboflavin (DelBoca et al, 1996).”
MethodSelf-citationSchinka, J. A., Town, T., Abdullah, L. I., Crawford, F., Ordorica, P. I., Francis, E. M., Hughes, P. H., Graves, A. B., Mortimer, J. A., & MULLAN, M. J. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4000951 · Cited by 97 · cited 1×
“…and/or drug dependence (Bergen et al, 1997; Berrettini et al, 1997; Bond et al, 1998; Kranzler et al, 1998; Sander et al, 1998; Gelernter et al, 1999; Town et al, 1999; Hoehe et al, 2000; Franke et al, 2001; Rommelspacher et al, 2001; Szeto et al, 2001; Schinka et al, 2002; Crowley et al, 2003).”
Naltrexone and the Treatment of Alcohol-Dependence: Initial Observations
Volpicelli, J. R., O’Brien, C. P., Alterman, A. I., & Hayashida, M. (1990) · Springer eBooks · doi:10.1007/978-1-4613-9000-8_11 · Cited by 95 · cited 3×
“Prior animal and human studies have demonstrated that the opioid system is involved in the reinforcing effects of alcohol (Volpicelli et al, 1986, 1990; Kreek, 1996).”
BackgroundSelf-citationFranke, P., Wang, T., N�then, M. M., Knapp, M., Neidt, H., Albrecht, S., Jahnes, E., Propping, P., & Maier, W. (2001) · American Journal of Medical Genetics · doi:10.1002/1096-8628(20010108)105:1<114::aid-ajmg1074>3.0.co;2-l · Cited by 94 · cited 1×
“…and/or drug dependence (Bergen et al, 1997; Berrettini et al, 1997; Bond et al, 1998; Kranzler et al, 1998; Sander et al, 1998; Gelernter et al, 1999; Town et al, 1999; Hoehe et al, 2000; Franke et al, 2001; Rommelspacher et al, 2001; Szeto et al, 2001; Schinka et al, 2002; Crowley et al, 2003).”
Anton, R. F., Moak, D. H., Latham, P. K., Waid, L. R., Malcolm, R. J., Dias, J. K., & Roberts, J. S. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200102000-00013 · Cited by 90 · cited 2×
“Since that time, the majority of clinical trials have established the benefits of naltrexone in the treatment of alcoholism (Oslin et al, 1997; Chick et al, 2000; Anton et al, 2001; Monterosso et al, 2001; Monti et al, 2001; Morris et al, 2001).”
BackgroundHuman μ‐Opioid Receptor Variation and Alcohol Dependence
Sander, T., Gscheidel, N., Wendel, B., Samochowiec, J., Smolka, M., Rommelspacher, H., Schmidt, L. G., & Hoehe, M. R. (1998) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.1998.tb05923.x · Cited by 89 · cited 1×
“…variation and the presence of alcohol and/or drug dependence (Bergen et al, 1997; Berrettini et al, 1997; Bond et al, 1998; Kranzler et al, 1998; Sander et al, 1998; Gelernter et al, 1999; Town et al, 1999; Hoehe et al, 2000; Franke et al, 2001; Rommelspacher et al, 2001; Szeto et al, 2001;…”
BackgroundSalmon, B., Hallmayer, J., Rogers, T., Kalaydjieva, L., Petersen, P. B., Nicholas, P., Pingree, C., McMahon, W., Spiker, D., Lotspeich, L., et al. (1999) · American Journal of Medical Genetics · doi:10.1002/(sici)1096-8628(19991015)88:5<551::aid-ajmg21>3.0.co;2-# · Cited by 85
Genetic analysis of the μ-opioid receptor in alcohol-dependent individuals
Rommelspacher, H., Smolka, M. N., Schmidt, L. G., Samochowiec, J., & Hoehe, M. R. (2001) · Alcohol · doi:10.1016/s0741-8329(01)00139-2 · Cited by 81 · cited 1×
“…and/or drug dependence (Bergen et al, 1997; Berrettini et al, 1997; Bond et al, 1998; Kranzler et al, 1998; Sander et al, 1998; Gelernter et al, 1999; Town et al, 1999; Hoehe et al, 2000; Franke et al, 2001; Rommelspacher et al, 2001; Szeto et al, 2001; Schinka et al, 2002; Crowley et al, 2003).”
Association of a functional ?-opioid receptor allele (+118A) with alcohol dependency
Town, T., Abdullah, L. I., Crawford, F., Schinka, J. A., Ordorica, P. I., Francis, E. M., Hughes, P. H., Duara, R., & MULLAN, M. J. (1999) · American Journal of Medical Genetics · doi:10.1002/(sici)1096-8628(19991015)88:5<458::aid-ajmg3>3.0.co;2-s · Cited by 79 · cited 1×
“…and/or drug dependence (Bergen et al, 1997; Berrettini et al, 1997; Bond et al, 1998; Kranzler et al, 1998; Sander et al, 1998; Gelernter et al, 1999; Town et al, 1999; Hoehe et al, 2000; Franke et al, 2001; Rommelspacher et al, 2001; Szeto et al, 2001; Schinka et al, 2002; Crowley et al, 2003).”
Human mu opioid receptor gene polymorphisms and vulnerability to substance abuse
BERRETTINI, W. H., HOEHE, M. R., FERRARO, T. N., DEMARIA, P. A., & GOTTHEIL, E. (1997) · Addiction Biology · doi:10.1080/13556219772598 · Cited by 77 · cited 1×
“…to demonstrate a consistent association between OPRM1 sequence variation and the presence of alcohol and/or drug dependence (Bergen et al, 1997; Berrettini et al, 1997; Bond et al, 1998; Kranzler et al, 1998; Sander et al, 1998; Gelernter et al, 1999; Town et al, 1999; Hoehe et al, 2000;…”
BackgroundSelf-citationAssociation of Alcohol or Other Drug Dependence with Alleles of the μ Opioid Receptor Gene (OPRM1)
Kranzler, H. R., Gelernter, J., O'Malley, S., Hernandez‐Avila, C. A., & Kaufman, D. (1998) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.1998.tb03919.x · Cited by 58 · cited 1×
“…between OPRM1 sequence variation and the presence of alcohol and/or drug dependence (Bergen et al, 1997; Berrettini et al, 1997; Bond et al, 1998; Kranzler et al, 1998; Sander et al, 1998; Gelernter et al, 1999; Town et al, 1999; Hoehe et al, 2000; Franke et al, 2001; Rommelspacher et al, 2001;…”
BackgroundSelf-citationμ-Opioid receptor variants and dopaminergic sensitivity in alcohol withdrawal
Smolka, M. N., Sander, T., Schmidt, L. G., Samochowiec, J., Rommelspacher, H., Gscheidel, N., Wendel, B., & Hoehe, M. R. (1999) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(99)00017-7 · Cited by 50
New Methodologies for Pharmacological Treatment Trials for Alcohol Dependence
Anton, R. F. (1996) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.1996.tb01183.x · Cited by 41 · cited 2×
“Although this definition of heavy drinking has been used in a number of pharmacotherapy trials (O’Malley et al, 1992; Volpicelli et al, 1992; Anton, 1996; Kranzler and VanKirk, 2001), both higher and lower levels of consumption could be considered significant.”
MethodPharmacogenomics and addiction to opiates
Lichtermann, D., Franke, P. E., Maier, W., & Rao, M. L. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00820-7 · Cited by 38 · cited 1×
“…been hypothesized that sequence variation in the gene encoding the m-receptor (genetic locus OPRM1), may result in a receptor with altered expression, structure or function, and as a consequence, increase or decrease an individual’s susceptibility to substance dependence (Lichtermann et al, 2000).”
Background
Research works printed but not linked: 2
- Thomas C, Wallack S, Swift R, Bishop C, McCarty D, Simoni-Wastila L (2001). Adoption of naltrexone in alcoholism treatment. J Addict Dis 20: 180.
- Volpicelli JR, Pettinati HM, McLellan AT, O'Brien CP (1997). BRENDA Manual: Compliance Enhancement Techniques with Pharmacotherapy for Alcohol and Drug Dependence. Guilford press: Philadelphia.
Cited by
DSM-5 criteria for substance use disorders: recommendations and rationale
Hasin, D. S., O’Brien, C. P., Auriacombe, M., Borges, G., Bucholz, K., Budney, A., Compton, W. M., Crowley, T., Ling, W., Petry, N. M., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.12060782 · Cited by 1,622
“, OPRM1 A118G and naltrexone response [124, 125]) Positron emission tomography (PET) imaging of brain functioning indicates that dopamine is associated with substance use (126, 127).”
BackgroundSelf-citationOpioid antagonists for alcohol dependence
Srisurapanont, M., & Jarusuraisin, N. (2002) · The Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001867 · Cited by 764
Should addictive disorders include non-substance-related conditions?
Potenza, M. N. (2006) · Addiction · doi:10.1111/j.1360-0443.2006.01591.x · Cited by 663
“As genetic factors have been associated with positive outcome for treatment of SUDs [81], genetic sampling should be considered in treatment trials in PG and other ICDs.”
BackgroundAlcoholism: A Systems Approach From Molecular Physiology to Addictive Behavior
Spanagel, R. (2009) · Physiological Reviews · doi:10.1152/physrev.00013.2008 · Cited by 634
The behavioral economics of substance use disorders: reinforcement pathologies and their repair
Bickel, W. K., Johnson, M. W., Koffarnus, M. N., MacKillop, J., & Murphy, J. G. (2014) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-032813-153724 · Cited by 655
“…a single nucleotide polymorphism in the OPRM1 gene (rs1799971) is associated with greater sensitivity to alcohol’s subjective effects (Ray & Hutchison 2004, 2007) and naltrexone’s clinical effects (Anton et al. 2008, Kim et al. 2009, Oslin et al. 2003), participants were genotyped for this locus.”
Background
Metadata
- Authors
- Oslin, D. W., Berrettini, W., Kranzler, H. R., Pettinati, H., Gelernter, J., Volpicelli, J. R., & O'Brien, C. P.
- Affiliations
- University of Pennsylvania (US)
- University of Connecticut (US)
- Yale University (US)
- Corresponding author
- Oslin, David W
- Venue
- Neuropsychopharmacology
- Published
- 2003-04-23
- Volume
- 28
- Issue
- 8
- Pages
- 1546-1552
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2074406420
- Cited by
- 571
- References
- 50
- Citations by year
- 2026: 2 · 2025: 10 · 2024: 4 · 2023: 3 · 2022: 7 · 2021: 9 · 2020: 13 · 2019: 18 · 2018: 13 · 2017: 13 · 2016: 20 · 2015: 31 · 2014: 36 · 2013: 34 · 2012: 58
- FWCI
- 10.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs
- University of Pennsylvania
- National Alliance for Research on Schizophrenia and Depression
- National Institutes of Health (5r01aa011062-05, AA03510)
- U.S. Public Health Service
- National Institute on Alcohol Abuse and Alcoholism (AA11330, AA-07517, R01AA011330, AA 13736, AA-03510, K24AA013736, AA 11062)
- National Institute of Mental Health (K08MH001599, MH 01599)
- National Institute on Drug Abuse (R01DA014008, DA 11385, DA 14008, DA001586)
- National Center for Research Resources (RR-06192, M01RR006192)
- NIH Clinical Center
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- mu-opioid receptor, OPRM1, naltrexone, alcoholism, genetic polymorphism, treatment response, relapse, abstinence, opioid system, pharmacogenetics
- MeSH terms
- Adult, Alcoholism, Female, Gene Frequency, Humans, Male, Middle Aged, Naltrexone, Polymorphism, Genetic, Confidence Intervals, Logistic Models, Odds Ratio, Survival Analysis, Receptors, Opioid, mu
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.